Name (Synonyms) | Correlation | |
---|---|---|
drug2964 | pregnant women with laboratory-confirmed 2019-n-CoV Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D014777 | Virus Diseases NIH | 0.12 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Due to the rapidly developing nature and severity of the COVID-19 pandemic, clinical trials involving a repurposed drug approach are the best option for rapidly identifying an effective COVID-19 therapeutic. The investigators propose to evaluate the efficacy of Montelukast in attenuating cytokine storm syndrome and ARDS via a randomized, blinded, placebo-controlled clinical trial. Specifically, our primary objective is comparing the efficacy of low-dose Montelukast versus placebo in reducing the risk of acute care visits and hospital admissions among COVID-19 positive patients in the general population.
Description: acute care use that includes a composite outcome comprised of being hospitalized and/or having visited an emergency room during follow-up.
Measure: Emergency Room Visits and Hospitalizations Time: 12 weeksDescription: The number of emergency room visits
Measure: Emergency room visit count Time: 12 weeksDescription: The number of hospitalizations
Measure: Hospitalization admission count Time: 12 weeksDescription: Complications will be defined as a composite endpoint including pneumonia, ARDS sepsis/septic shock, cardiomyopathy or arrhythmia, acute kidney injury, and secondary bacterial infections.
Measure: Time to other serious COVID-19 complications Time: 12 weeks